Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Loeber, G., Dworkin, M
The pulse it produces is sharp but brief, which is the single biggest practical limitation compared to modern alternatives
Publishers Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
The path to a longer, healthier, higher quality of life begins here
iCELLigence real-time cell analysis system for examining the cytotoxicity of drugs to cancer cell lines
